ORIC Stock Price, ORIC Pharmaceuticals Inc Quote, Chart

Market Summary

USD9.33+0.50

Market Closed

5.66%

ORIC Stock Price

View Fullscreen

ORIC RSI Chart

ORIC Valuation

Market Cap

628.6M

Price/Earnings (Trailing)

-6.24

Price/Sales (Trailing)

16.8K

Price/Free Cashflow

-7.26

ORIC Price/Sales (Trailing)

ORIC Profitability

Return on Equity

-44.94%

Return on Assets

-39.96%

Free Cashflow Yield

-13.77%

ORIC Fundamentals

ORIC Revenue

Revenue (TTM)

60.0K

ORIC Earnings

Earnings (TTM)

-100.7M

Earnings Growth (Yr)

-35.89%

Earnings Growth (Qtr)

-11.19%

Breaking Down ORIC Revenue

Last 7 days

15.5%

Last 30 days

-27.8%

Last 90 days

-19.0%

Trailing 12 Months

81.9%

How does ORIC drawdown profile look like?

ORIC Financial Health

Current Ratio

10.39

ORIC Investor Care

Shares Dilution (1Y)

49.42%

Diluted EPS (TTM)

-1.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	60.0K	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ORIC Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	chacko jacob	sold	-648,380	16.2095	-40,000	president and ceo
Feb 07, 2024	chacko jacob	sold	-320,186	12.295	-26,042	president and ceo
Feb 06, 2024	chacko jacob	sold	-169,160	12.1192	-13,958	president and ceo
Dec 15, 2023	piscitelli dominic	sold	-45,338	8.5835	-5,282	chief financial officer
Dec 15, 2023	chacko jacob	sold	-124,813	8.5847	-14,539	president and ceo
Dec 15, 2023	piscitelli dominic	sold	-	-	-14,042	chief financial officer
Dec 15, 2023	multani pratik s	acquired	-	-	14,042	chief medical officer
Dec 15, 2023	chacko jacob	acquired	-	-	38,667	president and ceo
Dec 15, 2023	multani pratik s	sold	-45,350	8.5859	-5,282	chief medical officer
Jul 11, 2023	chacko jacob	sold	-41,287	8.0076	-5,156	president and ceo

Which funds bought or sold ORIC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 30, 2024	Avior Wealth Management, LLC	new	-	110	110	-%
Apr 29, 2024	China Universal Asset Management Co., Ltd.	added	104	120,000	178,000	0.02%
Apr 25, 2024	Lindbrook Capital, LLC	added	78.5	3,284	5,253	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-3.02	490,642	1,582,490	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	new	-	27,005	27,005	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-1,000	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.35	-13,000	18,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	65,321	190,780	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	3,866,050	11,683,100	0.92%
Apr 15, 2024	Legato Capital Management LLC	new	-	317,625	317,625	0.04%

Are Funds Buying or Selling ORIC?

Are funds buying ORIC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORIC

No. of Funds

Unveiling ORIC Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	8.9%	6,275,210	SC 13G/A
Feb 13, 2024	prosight management, lp	2.9%	1,578,263	SC 13G/A
Feb 13, 2024	alkeon capital management llc	6.6%	3,604,096	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	blackrock inc.	4.5%	2,995,032	SC 13G/A
Feb 06, 2024	millennium management llc	0.0%	0	SC 13G/A
Feb 01, 2024	venrock healthcare capital partners iii, l.p.	6.6%	4,428,385	SC 13G
Jan 30, 2024	viking global investors lp	5.9%	4e+06	SC 13G
Jan 29, 2024	blackrock inc.	5.7%	3,095,648	SC 13G

Recent SEC filings of ORIC Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 11, 2024	10-K	Annual Report
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	S-3ASR	S-3ASR
Mar 11, 2024	SC 13G/A	Major Ownership Report
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to ORIC Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	5.56%	-15.17%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-2.25%	-24.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-4.35%	-11.20%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-6.50%	-24.30%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-22.91%	-44.64%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-9.87%	93.55%	-7.27	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-2.73%	5.06%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-18.02%	-34.57%	-9.66	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.68%	-20.30%	-45.81	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.49%	-8.60%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	0.22%	-33.81%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-1.95%	364.46%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-11.89%	28.44%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-44.78%	68.18%	-0.24	2.14	-13.45%	66.37%

ORIC Pharmaceuticals Inc News

Latest updates

ORIC Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)			(In Thousands)
Description	(%) Q/Q	2022Q3	2021Q3	2021Q2
Revenue	-	-	-	15.00
Operating Expenses	39.2%	25,694	18,456	21,057
S&GA Expenses	7.5%	5,971	5,557	5,540
Net Income	-34.7%	-24,829	-18,426	-21,009
Net Income Margin	-8.1%	-1.52	-1.40	-1.52
Free Cashflow	-59.4%	-19,721	-12,375	-16,349

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-8.1%	252	274	292	227	247	238	260	275	299	314	268	284	299	192	202	85.00	94.00	47.00
Current Assets	-8.5%	213	232	268	193	210	199	234	239	241	293	265	280	297	189	199	80.00	90.00	44.00
Cash Equivalents	-10.9%	23.00	26.00	104	59.00	67.00	29.00	49.00	113	226	241	170	104	78.00	62.00	197	79.00	89.00	43.00
Net PPE	-6.5%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00
Liabilities	3.7%	28.00	27.00	23.00	24.00	25.00	23.00	23.00	22.00	26.00	23.00	10.00	8.00	9.00	7.00	6.00	5.00	6.00	4.00
Current Liabilities	8.0%	20.00	19.00	15.00	15.00	15.00	13.00	12.00	12.00	15.00	12.00	10.00	8.00	9.00	7.00	6.00	5.00	5.00	3.00
Shareholder's Equity	-9.4%	224	247	269	203	222	215	237	253	273	292	258	276	290	184	195	-	-	-
Retained Earnings	-7.0%	-434	-406	-381	-358	-334	-313	-288	-268	-245	-222	-203	-182	-166	-138	-112	-101	-92.69	-65.81
Additional Paid-In Capital	0.7%	659	654	650	561	558	530	527	522	518	514	462	459	456	323	308	3.00	3.00	1.00
Shares Outstanding	0.6%	55.00	55.00	55.00	45.00	45.00	39.00	39.00	39.00	39.00	37.00	37.00	37.00	-	-	-	-	-	-
Float	-	-	-	415	-	-	-	172	-	-	-	522	-	-	-	743	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-23.5%	-24,270	-19,645	-21,145	-20,628	-15,329	-19,320	-17,776	-22,718	-16,284	-12,142	-16,214	-14,901	-17,825	-9,580	-9,584	-8,279	-7,148	-5,360	-5,494	-5,531	-
Share Based Compensation	1.5%	3,923	3,864	3,825	3,614	3,130	3,293	4,092	3,945	3,499	3,397	3,213	2,744	1,689	1,681	1,381	527	442	271	190	191	-
Cashflow From Investing	136.2%	20,963	-57,831	-19,313	12,778	28,300	-685	-46,203	-90,660	351	35,072	82,365	40,647	-91,256	-124,690	-202	189	-56.00	-219	-393	-100	-
Cashflow From Financing	1361.3%	453	31.00	85,174	-	24,793	1.00	415	16.00	813	48,586	-281	16.00	125,496	-341	126,986	-1,627	-61.00	5,698	49,923	15,264	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ORIC Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 85,172	$ 61,680
General and administrative	25,608	25,087
Acquired in-process research and development	0	5,000
Total operating expenses	110,780	91,767
Loss from operations	(110,780)	(91,767)
Other income:
Other income, net	10,083	2,645
Net loss	(100,697)	(89,122)
Other comprehensive loss:
Unrealized loss on Unrealized gain (loss) on investments	1,549	(1,188)
Comprehensive loss	$ (99,148)	$ (90,310)
Net loss per share, basic	$ (1.96)	$ (2.25)
Net loss per share, diluted	$ (1.96)	$ (2.25)
Weighted-average shares outstanding, basic	51,450,848	39,655,260
Weighted-average shares outstanding, diluted	51,450,848	39,655,260

ORIC Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,384	$ 66,840
Short-term investments	184,803	139,432
Prepaid expenses and other current assets	4,410	4,185
Total current assets	212,597	210,457
Long-term investments	26,852	21,951
Property and equipment, net	2,862	3,253
Other assets	9,696	11,517
Total assets	252,007	247,178
Current liabilities:
Accounts payable	944	1,320
Accrued liabilities	19,514	14,068
Total current liabilities	20,458	15,388
Other long-term liabilities	7,461	9,439
Total liabilities	27,919	24,827
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 54,865,553 and 45,089,537 shares issued and outstanding at December 31, 2023 and 2022, respectively	6	5
Additional paid-in capital	658,751	557,867
Accumulated deficit	(434,927)	(334,230)
Accumulated other comprehensive income (loss)	258	(1,291)
Total stockholders' equity	224,088	222,351
Total liabilities and stockholders' equity	$ 252,007	$ 247,178

About ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

CEO	Dr. Jacob M. Chacko M.B.A., M.D.
WEBSITE	oricpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	89

ORIC Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ORIC Pharmaceuticals Inc? What does ORIC stand for in stocks?

ORIC is the stock ticker symbol of ORIC Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ORIC Pharmaceuticals Inc (ORIC)?

As of Wed May 01 2024, market cap of ORIC Pharmaceuticals Inc is 628.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORIC stock?

You can check ORIC's fair value in chart for subscribers.

What is the fair value of ORIC stock?

You can check ORIC's fair value in chart for subscribers. The fair value of ORIC Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ORIC Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORIC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ORIC Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ORIC is over valued or under valued. Whether ORIC Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ORIC Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORIC.

What is ORIC Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 01 2024, ORIC's PE ratio (Price to Earnings) is -6.24 and Price to Sales (PS) ratio is 16.82 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORIC PE ratio will change depending on the future growth rate expectations of investors.